Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

8.26
-0.1700-2.02%
Post-market: 8.260.00000.00%19:40 EDT
Volume:2.70M
Turnover:22.36M
Market Cap:729.60M
PE:-2.60
High:8.60
Open:8.43
Low:8.17
Close:8.43
52wk High:12.49
52wk Low:5.41
Shares:88.33M
Float Shares:63.99M
Volume Ratio:2.80
T/O Rate:4.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1784
EPS(LYR):-3.1784
ROE:-94.82%
ROA:-25.33%
PB:4.19
PE(LYR):-2.60

Loading ...

Kura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial

TIPRANKS
·
Oct 01, 2025

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of Npm1 and Flt3 Mutations in Patients With Newly Diagnosed Acute Myeloid Leukemia (Aml)

THOMSON REUTERS
·
Oct 01, 2025

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

GlobeNewswire
·
Oct 01, 2025

Kura Oncology (KURA) Gets a Buy from Citizens JMP

TIPRANKS
·
Sep 30, 2025

Kura Oncology Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 30, 2025

Kura Oncology Executives Cash In: Massive Stock Sales Unveiled!

TIPRANKS
·
Sep 30, 2025

Kura Oncology COO Kathleen Ford Reports Disposal of Common Shares

Reuters
·
Sep 30, 2025

Kura Oncology Chief Medical Officer Mollie Leoni Reports Disposal of Common Shares

Reuters
·
Sep 30, 2025

BRIEF-Kura Oncology And Kyowa Kirin Announce First Patient Dosed In Pivotal Phase 3 Komet-017 Trial

Reuters
·
Sep 30, 2025

Kura Oncology announces first patient dosed in KOMET-017 clinical trial

TIPRANKS
·
Sep 30, 2025

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

GlobeNewswire
·
Sep 30, 2025

Kura, Kyowa Kirin Report Ziftomenib Met Primary Endpoint in Phase 2 Leukemia Trial

MT Newswires Live
·
Sep 26, 2025

Kura Oncology’s ziftomenib meets primary endpoint in AML study

TIPRANKS
·
Sep 26, 2025

Kura Oncology Announces Positive Pivotal Trial Results for Ziftomenib in Relapsed/Refractory NPM1-Mutated AML; FDA Priority Review Underway

Reuters
·
Sep 26, 2025

Kura Oncology Inc. to Participate in UBS Virtual Oncology Day Investor Conference

Reuters
·
Sep 24, 2025

Jefferies Sticks to Its Buy Rating for Kura Oncology (KURA)

TIPRANKS
·
Sep 18, 2025

Barclays Remains a Buy on Kura Oncology (KURA)

TIPRANKS
·
Sep 18, 2025

Wedbush Keeps Their Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
Sep 17, 2025

Promising Developments in Kura Oncology’s FTI Programs Highlighted by Analyst Buy Rating

TIPRANKS
·
Sep 17, 2025

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

GlobeNewswire
·
Sep 17, 2025